Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug

نویسندگان

  • Jin Mizushima
  • Keisuke Takahata
  • Noriko Kawashima
  • Motoichiro Kato
چکیده

Dopamine dysregulation syndrome (DDS) consists of a series of complications such as compulsive use of dopaminergic medications, aggressive or hypomanic behaviors during excessive use, and withdrawal states characterized by dysphoria and anxiety, caused by long-term dopaminergic treatment in patients with Parkinson's disease (PD). Although several ways to manage DDS have been suggested, there has been no established treatment that can manage DDS without deterioration of motor symptoms. In this article, we present a case of PD in whom the administration of the dopamine D2 partial agonistic antipsychotic drug aripiprazole improved DDS symptoms such as craving and compulsive behavior without worsening of motor symptoms. Considering the profile of this drug as a partial agonist at D2 receptors, it is possible that it exerts its therapeutic effect on DDS by modulating the dysfunctional dopamine system.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose

Although all current antipsychotics act by interfering with the action of dopamine at dopamine D2 receptors, two recent reports showed that 800 to 1000 mg of cannabidiol per day alleviated the signs and symptoms of schizophrenia, although cannabidiol is not known to act on dopamine receptors. Because these recent clinical findings may indicate an important exception to the general rule that all...

متن کامل

D2 receptor agonists and partial agonists: relationship between receptor binding measures and functional activity.

The neurotransmitter dopamine has been implicated in the aetiology of brain disorders such as Parkinson’s disease and schizophrenia, and dopamine receptors provide important targets for anti-parkinsonian and antipsychotic drugs. In particular, the beneficial use of dopamine D2 or DI/D2 agonists in the drug treatment of Parkinson’s disease is now well established [l], although the ideal agonist ...

متن کامل

Discriminative stimulus properties of N-desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice.

N-desmethylclozapine (NDMC) is the major active metabolite of the atypical antipsychotic drug clozapine and may contribute to the therapeutic efficacy of clozapine. Although they share many pharmacological features, it is noteworthy that NDMC is a partial dopamine D2 and cholinergic muscarinic M1/M4 agonist, whereas clozapine is a weak dopamine D2 receptor inverse agonist/antagonist and a nonse...

متن کامل

Partial Dopamine Agonists and the Treatment of Psychosis

Pharmacologic approaches that diminish dopamine-mediated neural transmission in brain have antipsychotic actions in humans. Blockade of D2 family dopamine receptors is the most common strategy. A paradoxical strategy of using dopamine agonists in particular circumstances to similarly diminish dopaminergic transmission is based on the known function of dopamine autoreceptors and on consideration...

متن کامل

Do dopamine partial agonists have partial efficacy as antipsychotics?

CNS Spectr 13:4 April 2008 279 NEW TREND IN PSYCHOPHARMACOLOGY Dopamine (D)2 partial agonists (DPAs) activate D2 receptors in a manner that is less than the full agonist dopamine yet more than full antagonists (eg, most known antipsychotics). Various DPAs span the spectrum between full agonist at one end and antagonists at the other, with the antipsychotic aripiprazole close to the antagonist e...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 11  شماره 

صفحات  -

تاریخ انتشار 2012